BSV portfolio can touch ₹5,000 cr in 3-4 yrs'
Business Standard|July 29, 2024
In one of the biggest pharmaceutical (pharma) deals in recent years, Delhi-based Mankind Pharma acquired Mumbai-headquartered specialty pharma company Bharat Serums and Vaccines (BSV) for ₹13,630 crore on Friday. RAJEEV JUNEJA, managing director (MD) and vice-chairman of Mankind Pharma, spoke to Sohini Das over the phone about the potential of the BSV portfolio to reach a ₹5,000 crore turnover in three to four years with Mankind's marketing prowess. Edited excerpts:
Sohini Das

Will this deal lead to Mankind Pharma focusing on exports too?

We have been very clear from the beginning that we don't want to get into exports with generic or me-too products. We always wanted products with a high level of entry barriers and complexity.

With the BSV deal, we now have branded products in some cases, there is no competition, and in others, there is limited competition (one or two players). For example, consider the AntiD product that BSV hasnearly 5-7 per cent of Indian mothers are Rh negative (blood group), which amounts to 8-10 million mothers.

Lack of preventive measures can cause brain damage or jaundice in & newborns. The mother needs to take a dose in the third trimester and within 72 hours after delivery with an Rh-positive child. Only 3040 per cent of expecting mothers adhere to this due to lack of awareness. BSV has the world's first and only recombinant for AntiRhoD, which has a valid patent until 2028. It also has vertically integrated in-house cell lines. If anyone tries to make any product of BSV, it would take five to 10 years at least. But we also feel there is huge potential for these products in the Indian market itself. Even after acquiring BSV, 87 per cent of the revenues of the entity will come from India. Wherever we have strong opportunities in the rest of the world, we will pursue them. Our ambition is to become a great company in India.

How do you wish to grow the synergies between BSV and Mankind?

Probably the fastest-growing therapy segment is infertility treatment. People are marrying late, then deciding to have a baby later on in their lives, focusing on careers, stress-myriad factors are affecting fertility.

This story is from the July 29, 2024 edition of Business Standard.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

This story is from the July 29, 2024 edition of Business Standard.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

MORE STORIES FROM BUSINESS STANDARDView All
Business Standard

Avoid partial payout: Buy health cover with fewer sub-limits

At a recent Confederation of Indian Industry (CII) summit, Satyajit Tripathi, member (distribution), Insurance Regulatory and Development Authority of India (Irdai), highlighted that grievances in general insurance, especially health insurance, mainly revolve around claim payments.

time-read
2 mins  |
September 17, 2024
'Largecaps appear reasonably valued'
Business Standard

'Largecaps appear reasonably valued'

Investors entering equities should come in with a long-term horizon to ensure short-term fluctuations amid high valuations do not derail the wealth generation, says DEEPAK SHENOY, chief executive officer and founder of Capitalmind.

time-read
3 mins  |
September 17, 2024
Business Standard

Sustained FPI activity lifts Sensex, Nifty

Equity benchmark index Sensex rebounded nearly 100 points to hit a lifetime closing high on Monday and Nifty scaled an intraday record level, propelled by bargain hunting in energy, utility and banking stocks amid sustained foreign fund inflows.

time-read
1 min  |
September 17, 2024
Business Standard

Investors may book partial profit: Brokerages

Analysts on Monday attributed the blockbuster debut of Bajaj Housing Finance Ltd (BHFL) on the bourses to its strong fundamentals and the brand 'Bajaj', and said it could emerge as a long-term wealth creator.

time-read
2 mins  |
September 17, 2024
Interest, trust of investors humbling: Sanjiv Bajaj
Business Standard

Interest, trust of investors humbling: Sanjiv Bajaj

Sanjiv Bajaj, chairman and managing director of Bajaj Finserv, on Monday said he expected 12-15 per cent credit growth in the housing finance industry, amid the strong tailwinds in the economy.

time-read
1 min  |
September 17, 2024
Business Standard

Trent may replace Bajaj Finserv in Sensexrejig in December

Bajaj Housing Finance Ltd's impressive stock market debut has brought cheer to the 100year-old Bajaj Group, but the conglomerate faces the prospect of Bajaj Finserv being removed from the benchmark Sensex index.

time-read
1 min  |
September 17, 2024
Business Standard

Sebi withdraws earlier statement on staff unrest

The Securities and Exchange Board of India (Sebi) on Monday said it was amicably addressing the concerns of its protesting employees on \"internal\" matters, as it withdrew an earlier press release that claimed that its staff's complaints were influenced by external elements.

time-read
1 min  |
September 17, 2024
Business Standard

The clash of 'will'power: The jury is still out

Following courtroom drama, experts analyse which one will dominate legal proceedings

time-read
3 mins  |
September 17, 2024
FIRST LINE OF DEFENCE
Business Standard

FIRST LINE OF DEFENCE

Why New Delhi is underlining the role of border villages as custodians of India's frontiers

time-read
4 mins  |
September 17, 2024
Business Standard

A fine balance

Markets in agriculture must be allowed to function

time-read
2 mins  |
September 17, 2024